- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 407/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Patent holdings for IPC class C07D 407/06
Total number of patents in this class: 375
10-year publication summary
|
20
|
22
|
27
|
32
|
17
|
21
|
16
|
14
|
9
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Eisai R&D Management Co., Ltd. | 1194 |
29 |
| Pro Farm Group, Inc. | 124 |
10 |
| Boehringer Ingelheim International GmbH | 4576 |
8 |
| Epics Therapeutics | 22 |
7 |
| BASF SE | 21131 |
6 |
| The Regents of the University of California | 20447 |
6 |
| Centre National de La Recherche Scientifique | 10830 |
6 |
| The Scripps Research Institute | 1342 |
6 |
| AstraZeneca AB | 2824 |
5 |
| Amgen Inc. | 4318 |
5 |
| H. Lundbeck A/S | 1246 |
5 |
| Biosplice Therapeutics, Inc. | 175 |
5 |
| Astellas Pharma Inc. | 1049 |
4 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3260 |
4 |
| Vitae Pharmaceuticals, Inc. | 94 |
4 |
| RiKarbon, Inc. | 13 |
4 |
| Glaxo Group Limited | 4264 |
3 |
| Bristol-myers Squibb Company | 4793 |
3 |
| Syngenta Participations AG | 1621 |
3 |
| Allergan, Inc. | 2259 |
3 |
| Other owners | 249 |